fda bans glp 1 compounding Did the Ban Compounded Semaglutide and Tirzepatide? GLP-1 Drugs: Brand Companies Push
Description
This morning, Ro dropped what is now the lowest entry point for an FDA approved GLP-1
Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant
Go beyond GLP-1s with key Longevity options
The association is specific to NAION
With these insights, doctors can tailor therapy so patients dont hit a plateau or miss out on potential benefits
You did it
